HomeCompareMIE vs MRK

MIE vs MRK: Dividend Comparison 2026

MIE yields 198.39% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MIE wins by $113.86M in total portfolio value
10 years
MIE
MIE
● Live price
198.39%
Share price
$3.85
Annual div
$7.64
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$113.92M
Annual income
$57,199,198.81
Full MIE calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MIE vs MRK

📍 MIE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMIEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MIE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MIE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MIE
Annual income on $10K today (after 15% tax)
$16,863.12/yr
After 10yr DRIP, annual income (after tax)
$48,619,318.99/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MIE beats the other by $48,610,722.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MIE + MRK for your $10,000?

MIE: 50%MRK: 50%
100% MRK50/50100% MIE
Portfolio after 10yr
$56.99M
Annual income
$28,604,656.30/yr
Blended yield
50.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MIE
Analyst Ratings
1
Sell
Consensus: Sell
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MIE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMIEMRK
Forward yield198.39%2.81%
Annual dividend / share$7.64$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$113.92M$57.7K
Annual income after 10y$57,199,198.81$10,113.78
Total dividends collected$107.31M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: MIE vs MRK ($10,000, DRIP)

YearMIE PortfolioMIE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$30,539$19,838.96$11,213$373.04+$19.3KMIE
2$89,299$56,622.55$12,667$512.06+$76.6KMIE
3$250,289$154,738.76$14,439$708.14+$235.8KMIE
4$673,140$405,330.47$16,640$988.16+$656.5KMIE
5$1,739,060$1,018,800.10$19,432$1,394.07+$1.72MMIE
6$4,320,677$2,459,883.17$23,057$1,992.90+$4.30MMIE
7$10,334,859$5,711,734.93$27,889$2,894.79+$10.31MMIE
8$23,826,716$12,768,416.58$34,518$4,286.29+$23.79MMIE
9$53,005,999$27,511,412.54$43,912$6,494.35+$52.96MMIE
10$113,915,617$57,199,198.81$57,714$10,113.78+$113.86MMIE

MIE vs MRK: Complete Analysis 2026

MIEStock

Cohen & Steers MLP Income & Energy Opportunity Fund, formerly Cohen & Steers MLP Income and Energy Opportunity Fund, Inc., is a non-diversified, closed-end management investment company. The Fund's investment objective is to provide attractive total return, consisted of high current income and price appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in energy-related master limited partnerships (MLPs) and companies that are involved in the exploration, production, gathering, transportation, processing, storage, refining, distribution or marketing of natural gas, natural gas liquids (including propane), crude oil, refined petroleum products, coal or other energy sources. The Fund also invests in marine shipping/offshore, chemicals, finance, real estate-diversified, technology-software, utilities, integrated telecommunications services and pipelines. Cohen & Steers Capital Management, Inc. is the investment advisor of the Fund.

Full MIE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MIE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MIE vs SCHDMIE vs JEPIMIE vs OMIE vs KOMIE vs MAINMIE vs JNJMIE vs ABBVMIE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.